kdm8 Antibody

What is KDM8 and why is it important in epigenetic research?

KDM8 (Lysine-specific demethylase 8), also called JMJD5, is a JmjC domain-containing histone demethylase that specifically targets H3K36me2. It functions as a transcriptional activator by inhibiting HDAC recruitment via demethylation of H3K36me2, which is typically considered an epigenetic repressive mark . KDM8 plays a crucial role in cell cycle progression, particularly at the G2/M phase transition, making it an important target in cell cycle regulation studies .

KDM8 has gained significant research interest because it is overexpressed in several cancer types including breast, prostate, thyroid, adrenal, bladder, uterine, and liver cancers . In breast cancer cells, KDM8 expression is significantly higher compared to normal human mammary epithelial cells, with 97.5% of tumor samples showing intense KDM8 staining compared to 67.5% in normal tissues . This pattern of overexpression suggests KDM8 may contribute to oncogenic processes, making it an important target for both basic and translational research.

What techniques can KDM8 antibodies be used for in laboratory research?

KDM8 antibodies can be employed in multiple experimental techniques essential for studying this protein's expression, localization, and function:

• Western Blotting (WB): The most common application, with recommended dilutions typically around 1:200-1:1000 depending on the specific antibody .

• Immunohistochemistry (IHC): Used for detecting KDM8 in tissue samples, as demonstrated in breast cancer tissue microarrays .

• Chromatin Immunoprecipitation (ChIP): Used to study KDM8 binding to target genes, such as its association with the cyclin A1 coding region .

• Immunoprecipitation (IP): Used to isolate KDM8-containing protein complexes and study its interactions with other proteins like AR and PKM2 .

• Immunofluorescence: Used for cellular localization studies, particularly useful when studying nuclear translocation of KDM8 or its binding partners .

Each technique requires specific optimization parameters, including antibody concentration, incubation time, and buffer conditions to maximize signal-to-noise ratio.

How should researchers select an appropriate KDM8 antibody for their experiments?

When selecting a KDM8 antibody, researchers should consider:

• Antibody specificity: Verify that the antibody has been validated to specifically recognize KDM8 without cross-reactivity to other JmjC domain-containing proteins.

• Host species: Consider compatibility with other antibodies in multi-labeling experiments. Most KDM8 antibodies are rabbit-derived, like the polyclonal antibody described in the search results .

• Clonality: Polyclonal antibodies offer higher sensitivity through multiple epitope recognition, while monoclonals provide better specificity and lot-to-lot consistency.

• Validated applications: Ensure the antibody has been verified for your specific application (WB, IHC, ChIP, etc.) .

• Species reactivity: Confirm the antibody recognizes KDM8 in your experimental species. Some antibodies, like the one described, react with human, mouse, and rat KDM8 .

• Immunogen information: Understanding which region of KDM8 the antibody targets can help predict potential binding to isoforms or variants.

For experiments requiring detection of specific post-translational modifications or protein-protein interactions, specialized antibodies may be needed.

What are the optimal conditions for Western blot detection of KDM8?

For optimal Western blot detection of KDM8 (calculated MW ~47 kDa), researchers should follow these methodological guidelines:

• Sample preparation:

  • Use appropriate lysis buffers containing protease inhibitors to prevent degradation

  • Include phosphatase inhibitors if studying phosphorylation states

  • Breast cancer cell lines like MCF7 or prostate cancer cell lines like LNCaP can serve as positive controls, while normal epithelial cells provide lower expression controls

• Gel electrophoresis and transfer:

  • Use 8-10% SDS-PAGE gels for optimal resolution

  • Ensure complete transfer of higher molecular weight proteins

• Antibody incubation:

  • Block membranes sufficiently (typically 5% non-fat milk or BSA)

  • Use recommended dilution (typically 1:200-1:1000 for KDM8 antibodies)

  • Incubate at 4°C overnight for improved signal-to-noise ratio

• Detection and validation:

  • Include knockdown/knockout controls to confirm specificity (shRNA-KDM8 cells as negative controls)

  • Verify molecular weight (47 kDa for KDM8)

  • Consider loading controls for nuclear proteins (H3, Lamin B1)

Western blotting has been successfully used to detect differential KDM8 expression between normal and cancer cells, with breast cancer cells showing significantly higher expression than human mammary epithelial cells (HMECs) .

How should ChIP assays with KDM8 antibodies be optimized?

Chromatin immunoprecipitation (ChIP) with KDM8 antibodies requires careful optimization to study KDM8 genomic binding:

• Crosslinking and chromatin preparation:

  • Standard 1% formaldehyde crosslinking (10 minutes at room temperature)

  • Sonication parameters should be optimized to yield DNA fragments of 200-500bp

  • Verify fragmentation efficiency by gel electrophoresis

• Immunoprecipitation:

  • Pre-clear chromatin with protein A/G beads to reduce background

  • Use 2-5 μg of KDM8 antibody per ChIP reaction

  • Include IgG control to assess non-specific binding

  • Include positive control targets (e.g., cyclin A1 exon 2 region)

• Analysis methods:

  • For targeted analysis, design primers spanning regions of interest (promoters and gene bodies)

  • For genome-wide analysis, ChIP-seq or ChIP-on-chip methodologies can be employed

• Validation strategies:

  • Use qPCR to validate enrichment at expected target sites

  • Employ knockdown/knockout controls to confirm specificity

  • Include known target regions (cyclin A1 coding region) as positive controls

Published studies have successfully used ChIP with KDM8 antibodies applied to human genome tiling arrays to identify that KDM8 occupies the coding region (specifically exon 2) of cyclin A1 rather than its promoter, demonstrating KDM8's role in transcriptional regulation .

What controls are essential when using KDM8 antibodies for immunoprecipitation studies?

When conducting immunoprecipitation (IP) with KDM8 antibodies to study protein interactions, the following controls are essential:

• Input control:

  • Reserve 5-10% of pre-IP lysate to confirm target protein presence

  • Use for normalization in quantitative analyses

• Negative controls:

  • IgG from the same species as the KDM8 antibody to assess non-specific binding

  • Isotype-matched control antibodies

  • Immunoprecipitation from KDM8 knockdown/knockout cells

• Reciprocal IP:

  • Perform reverse IP with antibodies against suspected interaction partners

  • Confirmed interactions should be detectable bidirectionally (as shown with KDM8-PKM2 interaction)

• Competitive peptide controls:

  • Pre-incubate antibody with immunizing peptide to block specific binding

• Washing stringency assessment:

  • Optimize salt and detergent concentrations in wash buffers

  • Balance between reducing background and maintaining specific interactions

IP studies have successfully demonstrated KDM8's interaction with androgen receptor (AR) and pyruvate kinase M2 (PKM2) in prostate cancer cells, with validation through reciprocal IP approaches . These protein-protein interactions connect KDM8's epigenetic functions to metabolic reprogramming and hormone signaling in cancer.

How can KDM8 antibodies be utilized to study cancer progression mechanisms?

KDM8 antibodies enable sophisticated investigations into cancer progression through multiple approaches:

• Expression profiling across cancer stages:

  • Utilize IHC with KDM8 antibodies on tissue microarrays to correlate expression with disease progression

  • Research has demonstrated KDM8 overexpression in 97.5% of breast tumor samples compared to 67.5% in normal tissues

  • Similar overexpression has been observed in prostate cancer and multiple other cancer types

• Mechanistic studies of cell cycle dysregulation:

  • Combine KDM8 immunodetection with cell cycle analysis

  • Flow cytometry of propidium iodide-stained cells has shown KDM8 knockdown leads to G2/M phase arrest (40% versus 20% in control cells)

  • Monitor cyclin A1 expression levels, which are directly regulated by KDM8

• Castration-resistance in prostate cancer:

  • KDM8 overexpression can drive androgen-independent growth in LNCaP cells

  • In vivo models have shown KDM8-overexpressing tumors continue growing after castration while control tumors regress

  • KDM8 antibodies can track protein expression and localization during this transition

• Multi-omics integration:

  • Combine ChIP-seq using KDM8 antibodies with RNA-seq to correlate binding with expression changes

  • Transcriptome analysis has revealed KDM8 overexpression activates androgen response genes even in the absence of DHT

Understanding KDM8's role in cancer progression may reveal new therapeutic vulnerabilities, as studies have shown KDM8 knockdown inhibits proliferation of cancer cell lines while having minimal effect on non-malignant cells .

What methodological approaches can detect KDM8 interactions with AR and PKM2?

Investigating KDM8's dual role as a coactivator of both AR (androgen receptor) and PKM2 (pyruvate kinase M2) requires specialized methodological approaches:

• Co-immunoprecipitation optimization:

  • Use reciprocal IP with antibodies against KDM8, AR, and PKM2

  • Optimize cell lysis conditions to preserve nuclear protein complexes

  • Consider crosslinking to capture transient interactions

  • Study has confirmed KDM8-AR and KDM8-PKM2 associations using this approach

• Domain mapping experiments:

  • Utilize antibodies recognizing different domains to isolate specific interaction regions

  • Studies with deletion mutants determined KDM8 interacts with AR's ligand-binding domain rather than its N-terminal domain

• Nuclear translocation assays:

  • Cell fractionation followed by immunoblotting shows KDM8 enhances PKM2 nuclear translocation

  • Quantitative confocal microscopy can track fluorescent intensity of PKM2 across nuclei

• Functional interaction studies:

  • Chromatin immunoprecipitation (ChIP) to detect co-occupancy at target genes

  • Luciferase reporter assays to measure transcriptional effects

  • Unsupervised clustering analysis of transcriptome data revealed KDM8 modulates androgen response genes

• Proximity ligation assays:

  • Detect protein-protein interactions in situ with higher sensitivity than conventional co-localization

These methodological approaches have revealed that KDM8 serves as an integrator of AR signaling and cancer metabolism by interacting with both AR and PKM2, contributing to castration resistance in prostate cancer .

How can researchers differentiate between enzymatic and non-enzymatic functions of KDM8 using antibodies?

Distinguishing between KDM8's histone demethylase activity and its potential non-enzymatic functions requires sophisticated experimental design:

• Enzymatic activity assessment:

  • Use antibodies against H3K36me2 to monitor KDM8's demethylase activity

  • Immunoblotting shows KDM8 knockdown increases H3K36me2 levels

  • ChIP with H3K36me2 antibodies can map changes in this mark at KDM8 target genes

• Rescue experiments with catalytic mutants:

  • Compare wild-type KDM8 with catalytic mutant in functional assays

  • Cell proliferation assays demonstrated that induction of wild-type KDM8, but not catalytic mutant, stimulated cell growth

  • This approach separates enzymatic from scaffolding functions

• Combined ChIP strategies:

  • Sequential ChIP (re-ChIP) with KDM8 antibodies followed by H3K36me2 antibodies

  • Determine if all KDM8-bound regions show reduced H3K36me2 or if some functions are independent of demethylation

• Interactome analysis:

  • Immunoprecipitate KDM8 complexes and identify protein partners by mass spectrometry

  • Compare interactors of wild-type versus catalytically inactive KDM8

  • Studies have shown KDM8 interacts with AR and PKM2, possibly through mechanisms independent of its demethylase activity

• Temporal dynamics:

  • Time-course experiments tracking KDM8 binding, H3K36me2 levels, and gene expression

  • Determine if demethylation always precedes transcriptional changes

These approaches have revealed that while KDM8's demethylase activity is crucial for cell proliferation , its interactions with AR and PKM2 might represent additional functions potentially independent of histone modification .

What methodological considerations are important when studying KDM8 localization in cellular compartments?

KDM8's diverse functions may relate to its localization in different cellular compartments, requiring specific methodological considerations:

• Subcellular fractionation optimization:

  • Use optimized protocols for nuclear, cytoplasmic, and chromatin fractions

  • Include compartment-specific markers for validation (e.g., Lamin B1 for nuclear fraction)

  • Western blot with KDM8 antibodies can detect protein distribution across fractions

• Immunofluorescence microscopy:

  • Fixation methods affect nuclear protein detection (paraformaldehyde versus methanol)

  • Include pre-extraction steps to remove soluble proteins if studying chromatin-bound fraction

  • Use confocal microscopy for higher resolution localization

  • Quantitative analysis of fluorescence intensity across nuclear regions can track translocation events

• Stimulus-dependent relocalization:

  • Track KDM8 localization under different conditions (e.g., hormone stimulation)

  • Time-course experiments to capture dynamic changes

  • KDM8 has been shown to enhance nuclear translocation of PKM2

• Co-localization with interaction partners:

  • Dual immunofluorescence with AR or PKM2 antibodies

  • Calculate co-localization coefficients quantitatively

  • Super-resolution microscopy for more precise spatial relationships

• Chromatin association dynamics:

  • Combine fractionation with ChIP to determine chromatin-bound versus soluble nuclear KDM8

  • Assess cell cycle-dependent changes in localization

Studies using cell fractionation and confocal microscopy have demonstrated that KDM8 not only localizes to the nucleus but also enhances the nuclear translocation of PKM2, linking epigenetic regulation to metabolic reprogramming in cancer cells .

What are common pitfalls when using KDM8 antibodies and how can they be addressed?

Researchers may encounter several challenges when working with KDM8 antibodies that require specific troubleshooting approaches:

• Low signal detection:

  • Optimize antibody concentration (try 1:200-1:1000 for Western blot)

  • Extend incubation time (overnight at 4°C)

  • Use enhanced detection systems (high-sensitivity ECL reagents)

  • Enrich for nuclear fraction when detecting endogenous KDM8

  • Consider that normal cells express low levels of KDM8 compared to cancer cells

• High background:

  • Increase blocking duration and concentration

  • Add Tween-20 to antibody dilution buffer (0.1-0.3%)

  • Optimize washing steps (more frequent changes, longer durations)

  • For immunofluorescence, include an autofluorescence quenching step

• Non-specific bands:

  • Use KDM8 knockdown controls to identify specific bands

  • Consider using monoclonal antibodies for higher specificity

  • Include peptide competition controls

  • The expected molecular weight of KDM8 is approximately 47 kDa

• Batch-to-batch variation:

  • Validate new antibody lots against previous successful experiments

  • Maintain consistent application parameters

  • Consider creating an internal reference standard

• ChIP optimization:

  • Titrate antibody amount (2-5 μg per ChIP reaction is typical)

  • Optimize chromatin fragmentation specifically for KDM8 target regions

  • Include spike-in controls for quantitative ChIP experiments

When troubleshooting, remember that KDM8 is primarily nuclear, has a calculated molecular weight of 47 kDa, and shows higher expression in cancer cells compared to normal tissues .

How can researchers validate the specificity of KDM8 antibodies?

Rigorous validation of KDM8 antibody specificity is essential for generating reliable research data:

• Genetic knockdown/knockout controls:

  • Compare signal between wild-type and KDM8 knockdown cells

  • Studies have used shRNA-KDM8-MCF7 cells as negative controls

  • siRNA targeting KDM8 in MCF10A cells verified specificity in immunoblot analysis

• Overexpression controls:

  • Compare endogenous versus overexpressed KDM8 signal

  • Inducible expression systems provide internal controls

  • Tagged KDM8 can be detected with tag-specific antibodies for cross-validation

• Peptide competition assays:

  • Pre-incubate antibody with immunizing peptide or recombinant KDM8

  • Signal should diminish proportionally to peptide concentration

• Cross-reactivity assessment:

  • Test against related JmjC domain-containing proteins

  • Evaluate in multiple species if claiming cross-reactivity (human, mouse, rat)

• Multi-technique concordance:

  • Compare results across different applications (WB, IP, IHC, IF)

  • Consistent detection patterns increase confidence in specificity

  • Similar expression patterns observed in tissue samples versus cell lines support specificity

• Mass spectrometry validation:

  • Immunoprecipitate with KDM8 antibody and verify identity by mass spectrometry

  • Confirm detection of KDM8 peptides and expected interacting partners

Thorough validation ensures experimental results reflect true KDM8 biology rather than antibody artifacts.

How can KDM8 antibodies contribute to understanding cancer therapy resistance mechanisms?

KDM8 antibodies enable investigation of therapy resistance mechanisms through several sophisticated approaches:

• Expression correlation with treatment response:

  • IHC with KDM8 antibodies on patient samples pre- and post-treatment

  • Studies have shown KDM8 overexpression drives castration-resistance in prostate cancer models

  • KDM8 knockdown inhibited proliferation of enzalutamide-resistant prostate cancer cells (C4-2B-MDVR)

• Dynamic changes during resistance development:

  • Time-course experiments tracking KDM8 expression during resistance acquisition

  • Cell fractionation and immunoblotting to monitor subcellular localization changes

  • LNCaP cells overexpressing KDM8 continued tumor growth after castration, unlike control tumors

• Mechanistic pathway analysis:

  • ChIP-seq with KDM8 antibodies to identify altered binding patterns in resistant cells

  • Compare transcriptome profiles of KDM8-modulated genes between sensitive and resistant states

  • Unsupervised clustering analysis revealed KDM8 activates androgen response genes even without androgen

• Therapeutic targeting assessment:

  • Monitor KDM8 expression and activity following experimental therapies

  • Evaluate potential combinatorial approaches targeting KDM8-dependent pathways

  • KDM8's interaction with both AR and PKM2 suggests targeting metabolic-epigenetic integration points

• Biomarker development:

  • Quantitative analysis of KDM8 expression in liquid biopsies

  • Correlation with other resistance markers

These approaches have revealed that KDM8 overexpression can drive hormone therapy resistance in prostate cancer, suggesting that monitoring KDM8 levels might predict treatment response and identifying KDM8 as a potential therapeutic target .

What methodological approaches can detect post-translational modifications of KDM8?

Investigating post-translational modifications (PTMs) of KDM8 requires specialized methodological approaches:

• Phosphorylation-state specific detection:

  • Use phosphatase inhibitors during sample preparation

  • Perform lambda phosphatase treatment as a negative control

  • Immunoprecipitate KDM8 followed by phospho-specific antibody detection

  • Consider Phos-tag gels for mobility shift detection

• Mass spectrometry-based PTM mapping:

  • Immunoprecipitate KDM8 with validated antibodies

  • Perform tryptic digestion and LC-MS/MS analysis

  • Include enrichment strategies for specific modifications (TiO₂ for phosphopeptides)

  • Compare PTM profiles under different cellular conditions

• Other modifications detection:

  • Ubiquitination: Immunoprecipitate under denaturing conditions to preserve ubiquitin linkages

  • Acetylation: Use deacetylase inhibitors during lysis

  • SUMOylation: Include SUMO protease inhibitors

• Functional consequence assessment:

  • Create site-specific mutants of modified residues

  • Compare enzymatic activity and protein interactions

  • Perform ChIP-seq with KDM8 antibodies on wild-type versus PTM-deficient mutants

• Stimulus-dependent PTM changes:

  • Time-course experiments following treatment with growth factors, stress inducers, or cell cycle synchronization

  • Monitor PTM changes in relation to subcellular localization and activity

While the search results don't directly address KDM8 post-translational modifications, understanding these modifications could provide insights into the regulation of KDM8's dual roles in histone demethylation and its interactions with AR and PKM2 .

How can researchers investigate the role of KDM8 in different cellular contexts using antibodies?

Investigating KDM8 function across different cellular contexts requires carefully designed experimental approaches:

• Tissue and cell type expression profiling:

  • Use KDM8 antibodies for tissue microarray analysis

  • Compare expression between normal and malignant tissues across multiple organs

  • Studies have shown KDM8 overexpression in multiple cancer types including breast, prostate, thyroid, adrenal, bladder, uterine, and liver cancers

• Conditional expression systems:

  • Generate inducible KDM8 expression models

  • Compare phenotypic outcomes in different cell backgrounds

  • KDM8 overexpression converted androgen-dependent LNCaP cells to androgen-independent growth

• Cell-state specific analysis:

  • Synchronize cells at different cell cycle stages to study phase-specific functions

  • KDM8 knockdown causes G2/M arrest, indicating cell cycle-dependent roles

  • Compare proliferating versus differentiated states

• Context-dependent interactome:

  • Perform immunoprecipitation with KDM8 antibodies in different cell types

  • Compare protein interaction partners between contexts

  • Studies demonstrated KDM8 interacts with AR in prostate cells and regulates cyclin A1 in breast cancer cells

• Signaling pathway integration:

  • Inhibit specific pathways and monitor effects on KDM8 function

  • Use phospho-specific antibodies to detect activation of related pathways

  • Transcriptome analysis revealed KDM8 affects androgen-responsive genes differently depending on DHT presence

These approaches have revealed context-specific functions of KDM8, including its role in cell cycle progression in breast cancer cells and its function in androgen signaling and metabolism in prostate cancer cells .